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Abstract
It has been widely accepted that prostaglandins are involved in peripheral mechanisms of hyperalgesia. Several lines of evidence suggest
that prostaglandins also contribute to the mechanisms underlying hyperalgesia at the level of the spinal cord. The nociceptive ﬂexor reﬂex of
the hind limb was used to test the hypothesis that products of cyclo-oxygenase contribute to the increased excitability of spinal neurons
during hyperalgesia induced by peripheral injection of complete Freund’s adjuvant (CFA) into the hind paw. The reﬂex was evoked by
electrical stimulation of the sural nerve at an intensity that activated A- and C-ﬁbers, and muscle potentials were recorded in hamstring
muscles in decerebrate, spinalized rats. Intrathecal administration of (S)-ibuprofen (1–100 nmol) dose-dependently attenuated the ﬂexor
reﬂex in CFA treated rats but had no effect in untreated rats. (R)-Ibuprofen had no effect on the reﬂex in either control or CFA-treated rats at
the dose tested (100 nmol). Western blots of lumbar spinal cord extracts showed increased levels of cyclo-oxygenase (COX)-2 protein in the
dorsal spinal cord of rats with peripheral inﬂammation; no change occurred in the level of COX-1. These results indicate that products of
COX-2 contribute to the increased excitability of the spinal cord during persistent peripheral inﬂammation.
q 2003 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.
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1. Introduction
Prostaglandins are recognized as signiﬁcant factors in the
sensitization of primary afferent neurons to thermal
(Handwerker, 1976; Mizumura et al., 1991) mechanical
(Schaible and Schmidt, 1988a,b; Birrell et al., 1991; Kress
et al., 1992; Schepelmann et al., 1992) and chemical stimuli
(Handwerker, 1976; Mense, 1981; Schepelmann et al.,
1992; Birrell et al., 1993; Stucky et al., 1996) following
tissue injury and induction of inﬂammation. In addition to
decreasing thresholds for generating action potentials and
increasing the number of evoked action potentials, prosta-
glandins enhance the release of proinﬂammatory peptides
(e.g. substance P and calcitonin gene-related peptide) from
terminals of primary afferent neurons within the site of
tissue injury (Hua et al., 1994). Induction of cyclo-
oxygenase 2 (COX-2), a rate limiting enzyme in the
synthesis of prostaglandins, at the site of tissue injury
(Seibert et al., 1994; Appleton et al., 1995) supports
the increased generation and release of prostaglandins
(Higgs and Salmon, 1979; Bombardieri et al., 1981).
In addition to sensitization of primary afferent neurons at
the site of tissue injury, it has become increasingly apparent
that prostaglandins also play a role in spinal mechanisms of
hyperalgesia. COX-1 and COX-2 are constitutively
expressed in the spinal cord (Willingale et al., 1997; Beiche
et al., 1998a; Yaksh et al., 2001), and levels of prostaglan-
dins increase in cerebral spinal ﬂuid or perfusate of the
spinal cord in response to persistent activation of C-ﬁbers
(Coderreetal.,1990;MalmbergandYaksh,1995;Hayetal.,
1997) and peripheral inﬂammation (Samad et al., 2001;
Smith et al., 1998). Occurrence of high densities of binding
sites for prostaglandin E2 (PGE2) in superﬁcial laminae of
the dorsal horn (Matsumura et al., 1992; Beiche et al.,
1998a,b), where small diameter primary afferent neurons
terminate, offer a substrate for physiological effects of
prostaglandins. Induction of thermal, mechanical and
chemical hyperalgesia (Taiwo and Levine, 1986; Uda
et al., 1990; Minami et al., 1994a,b; Saito et al., 1995)
following intrathecal administration of prostaglandins is
evidence that endogenous prostaglandins at the level of
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Observations that intrathecal administration of COX
inhibitors decrease behavioral responses to peripheral
formalin (Malmberg and Yaksh, 1992a; Yamamoto and
Nozaki-Taguchi, 1996; Dirig et al., 1997), as well as the
thermal (Dirig et al., 1998; Yaksh et al., 2001)a n d
mechanical (Samad et al., 2001) hyperalgesia associated
with peripheral inﬂammation, support a role for endogenous
prostaglandins in spinal mechanisms of hyperalgesia.
Although considerable behavioral data support a role for
spinal prostaglandins in contributing to hyperalgesia
associated with peripheral inﬂammation, there is little direct
evidence that inhibitors of COX affect neuronal excitability
at the level of the spinal cord in a model of inﬂammation.
Given observations of wide spread changes in spinal COX-2
activity in the central nervous system following induction of
peripheral inﬂammation (Beiche et al., 1998a; Samad et al.,
2001), it is important to address whether changes in spinal
neuron excitability occur after intrathecal administration of
COX inhibitors. We used the nociceptive ﬂexor reﬂex of the
hind limb to investigate the role of COX within the spinal
cord following the induction of persistent peripheral
inﬂammation by an intra-plantar injection of Complete
Freund’s Adjuvant (CFA) in rats. Previous studies have
shown that the increased magnitude of this reﬂex ipsilateral
to an inﬂamed paw is mediated by increased excitability of
spinal interneurons (Parsons et al., 1996). Ibuprofen, a non-
selective cyclo-oxygenase inhibitor, was used to test the
contribution of spinal COX in the facilitation of the reﬂex in
CFA-treated rats. In addition, Western blot analysis was
used to identify and localize changes in COX protein in the
spinal cord following induction of peripheral inﬂammation.
2. Materials and methods
Male Sprague–Dawley rats (250–320 g, Harlan Indus-
tries, Indianapolis, IN) were used in this study. All
experimental procedures involving animals were approved
by the Institutional Animal Care Use and Committee of the
University of Minnesota and conform to established
guidelines.
2.1. Induction of peripheral inﬂammation
Peripheral inﬂammation was induced by injection of
CFA (Calbiochem Corp., La Jolla, CA, emulsiﬁed 1:1 with
saline, 130–150 ml) beneath the skin of the plantar surface
of the left hind paw of an anesthetized rat (methohexital
sodium, 65 kg/kg, i.p.). For studies of COX protein, both
hind paws were injected with CFA. Occurrence of thermal
hyperalgesia and edema in CFA-treated rats was conﬁrmed
on the day of electrophysiological recording. Thermal
hyperalgesia was deﬁned as decreased latency of with-
drawal of the hind paw to a thermal stimulus. Paw
withdrawal latency was determined bilaterally using
a radiant heat source projected onto the plantar surface of
the hind paw of unrestrained rats (Hargreaves et al., 1988).
Evidence of edema was increased dorsal-ventral paw
thickness. Paw thickness was measured with calipers after
the animal was anesthetized.
2.2. Recording the nociceptive ﬂexor reﬂex
2.2.1. Measurement of the nociceptive ﬂexor reﬂex
CFA-treated rats were used 2–3 days after injection of
CFA.Surgical preparation of rats for recording of the ﬂexor-
reﬂex in our laboratory has been described previously in
detail (Parsons et al., 1996; Jia and Seybold, 1997). The
nociceptive ﬂexor reﬂex was elicited at 4 min intervals by
electrical stimulation of the sural nerve at either 200 £ the
threshold for activation of Ab ﬁbers or 2 £ the threshold for
C-ﬁbers. The mean stimulus intensity employed in the
present experiments was 1.1 ^ 0.1 mA (n ¼ 52) with a
pulse width of 0.5 ms. The number of compound action
potentials evoked in the hamstring muscles was recorded
using a bipolar needle electrode, and activity was integrated
within 1 s bins. The baseline reﬂex was stable for at least 30
min before administering any drug. To assess the effect of a
drug on the reﬂex, the average of four reﬂexes evoked by
sural nerve stimulation before drug administration was
deﬁned as baseline. Subsequent responses were calculated
as percent of the baseline reﬂex for that animal.
2.2.2. Drugs
(S)-Ibuprofen and (R)-ibuprofen were provided by T.L.
Yaksh (UC, San Diego). Ibuprofen was dissolved in 10% 2-
hydroxypropyl-b-cyclodextrin H-107 and diluted to work-
ing concentrations with phosphate buffered saline
(pH ¼ 7.2). The ﬁnal concentration of cyclodextrin in a
dose was no more than 5%; this concentration was used as
the vehicle control. Drugs were administered intrathecally
in a volume of 10 ml, and the tubing was ﬂushed with 10 ml
saline. In three experiments, (S)-ibuprofen (100 nmol) was
injected intravenously in 100 ml via an external jugular vein
and subcutaneously in 50 ml into the plantar surface of the
inﬂamed hind paw.
2.3. Western blots
2.3.1. Sample preparation
Animals were perfused with ice-cold phosphate buffered
saline (PBS, 0.05 M phosphate, pH 7.4) under surgical
anesthesia 48 h after injection of CFA, and spinal segments
L4–L5 were removed. The spinal tissue was divided into
dorsal and ventral halves that were treated separately. Each
tissue sample was weighed and sonicated in buffer (5 mM
dithiothreitol, 173 mM sodium dodecyl sulfate (SDS), 10
mM EDTA, in 0.05 M Tris–HCl, pH 6.8 with 10% glycerol
and 0.01% bromophenol blue; 45 ml/mg wet weight).
Following sonication, the samples were heated to 908C for
10 min, cooled to room temperature, and centrifuged at
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and stored at 2208C.
On the day of the assay, the samples were thawed, heated
to 958C for 5 min and cooled. A 10 ml aliquot of each spinal
cord sample was submitted to gel eletrotrophoresis on a pre-
cast 12% resolving, 4% stacking SDS/polyacrylamide gel
(200 V for 45 min; Bio-Rad, Hercules, CA). Following
electrophoresis, the proteins were transblotted onto Immo-
bilon-P transfer membrane (1 h at 100 V Millipore
Corporation, Bedford, MA).
2.3.2. Immunostaining
Prior to immunostaining, the membrane was incubated
with 3% non-fat dry milk in PBS for1 hat room temperature
and rinsed in PBS to diminish non-speciﬁc staining. The
membrane was then incubated in a primary antibody
overnight at 48C. Rabbit anti-COX-1 (1/500; Calbiochem,
San Diego, CA), rabbit anti-COX-2 (1/1000; Cayman
Chemical, Ann Arbor, MI) and mouse anti-b-tubulin III
(1/800 or 1/20,000; Sigma-Aldrich, St. Louis, MO) were
diluted in 5% BSA/PBS. The next day the membrane was
rinsed in PBS/0.05% Tween-20 (TPBS) and then incubated
in goat anti-rabbit peroxidase conjugate (1/7500 for COX-1;
1/10,000 for COX-2) or goat anti-mouse peroxidase
conjugate (1/10,000 or 1/20,000; Sigma-Aldrich) diluted
in 5% BSA/TPBS. Following incubation in secondary
antibody for 1 h at room temperature, the membrane was
rinsed in TPBS, saturated in SuperSignal West Pico
Chemiluminescent Substrate (Pierce, Rockford, IL) and
then apposed to X-ray ﬁlm (Eastman Kodak Company,
Rochester, NY). Bands of immunoreactive protein were
visualized following photographic development of the X-
ray ﬁlm. Each gel was stained sequentially for COX-1 or
COX-2-immunoreactivity and then b-tubulin-immunoreac-
tivity 13 days later (after chemiluminescence related to the
COX protein had decayed). The average pixel intensity in
each band on a gel was determined using NIH Image. To
control for variability in loading of samples, data for COX-
immunoreactivity are expressed as a percentage of the value
for b-tubulin immunoreactivity within the same sample.
CFA treatment did not induce a change in the amount of
tubulin-immunoreactivity in either the dorsal or ventral
halves of the spinal cord. COX-1 and COX-2 antisera bound
to commercially prepared samples of ovine COX-1 and
COX-2 (Cayman Chemical), respectively, that were run in
parallel with tissue samples. Neither antiserum cross-
reacted with the opposite isoform of the enzyme. Preincu-
bation of the diluted COX-2 antibody with the immunizing
peptide (1 mM) blocked immunostaining. The immunizing
peptide was not available for the COX-1 antibody.
2.4. Statistics
All data are reported as the mean ^ SEM for a group of
animals. Data were analyzed using one or two way-analysis
of variance and Tukey’s post-hoc test to identify differences
between groups. The signiﬁcance level was set at P , 0:05.
3. Results
3.1. Characteristics of CFA-induced inﬂammation
Consistent with previous reports from this laboratory
(Stucky et al., 1993; Galeazza et al., 1995), CFA-treated
animals exhibited classical signs of inﬂammation
2–3 days following CFA injection into the plantar
surface of the left hind paw. Edema in the injected
paw was evident as an increase in paw thickness:
CFA-injected paws were approximately twice as thick as
untreated paws in the dorsal-ventral dimension
(CFA-treated: 10.8 ^ 0.2 mm, n ¼ 17; untreated:
6.0 ^ 0.1 mm, n ¼ 14). In addition, paws injected with
CFA had a 40% reduction in latency for withdrawal in
response to a radiant heat stimulus (Fig. 1A) indicating
thermal hyperalgesia. Signs of inﬂammation occurred
only in the injected hind paw.
3.2. Flexor reﬂex in untreated and CFA-treated rats
3.2.1. Ongoing activity
In the absence of electrical stimulation, ongoing activity
in the hamstring muscle occurred more frequently in CFA-
treated animals compared to untreated rats (CFA: 76%;
n ¼ 21; untreated: 20%, n ¼ 20; P , 0:05, Fisher’s exact
test). Ongoing activity lasted longer than 10 min at the
beginning of the recording period and continued between
evoked reﬂexes (Fig. 2). This observation is consistent with
previous reports on CFA-treated rats in this model (Parsons
et al., 1996; Jia and Seybold, 1997). All the data reported for
the ﬂexor reﬂex are the number of potentials that occurred
above the level of ongoing activity.
3.2.2. Thresholds for activation of Ab,A d and C volley
in untreated and CFA-treated rats
The electrical threshold for exciting A- and C-ﬁber
components of the sural nerve compound action potential
were determined in order to deﬁne the electrical stimulus
for eliciting the ﬂexor reﬂex in each animal. The
thresholds for eliciting Ab,A d and C-ﬁber deﬂections
in the compound action potential are summarized in
Table 1. There were no differences between untreated and
CFA-treated animals in these thresholds. The absence of
differences indicates that peripheral inﬂammation did not
change excitability of peripheral axons. On the basis of
these data, the stimulus for the ﬂexor reﬂex was 2 £ the
C-ﬁber threshold or 200 £ the Ab-ﬁber threshold if a C-
ﬁber volley was not detectable. In spite of the variable
strategy, there was no difference in the stimulation
intensity used to evoke the ﬂexor reﬂex in untreated and
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3.2.3. The number of compound muscle potentials in
the evoked nociceptive ﬂexor reﬂex is greater in
CFA-treated rats compared to untreated rats
Although there was no difference between untreated and
CFA-treated animals in the ﬁrst 5 s of the nociceptive ﬂexor
reﬂex, which includes the peak response to the stimulus,
there is a marked increase in activity within 120 s following
the stimulus in CFA-treated rats (Fig. 1B). The increase in
activity within the 120 s period reﬂects an overall increase
in the duration of the muscle activity underlying the reﬂex in
CFA-treated rats following stimulation of the sural nerve
(Parsons et al., 1996).
3.3. (S)-Ibuprofen diminished the nociceptive ﬂexor reﬂex
in CFA-treated rats
Spinal administration of (S)-ibuprofen had no effect on
the short-latency (5 s, Fig. 3A) or long-latency (120 s,
Fig. 3B) components of the nociceptive ﬂexor reﬂex in
untreated rats at the doses tested (1–100 nmol) or at any one
time point within 50 min of drug administration (Fig. 4A).
In addition, (S)-ibuprofen had no effect on the short-latency
activity evoked in the hamstring muscles in CFA-treated
rats (Figs. 2 and 3A). However, the highest dose of (S)-
ibuprofen tested (100 nmol) inhibited the long-latency
activity of the reﬂex by approximately 25% from 10 to 30
min after spinal administration (Figs. 2–4B). The reﬂex
recovered to pre-drug levels after 1 h (Figs. 2 and 4B).
Injection of vehicle (5% cyclodextrin) had no effect on the
reﬂex in either untreated or CFA-treated rats (Fig. 4).
Inhibition of the reﬂex by (S)-ibuprofen was dose-
dependent (Fig. 3). Testing of doses greater than 100 nmol
was limited by the solubility of the drug. Intrathecal
administration of the stereoisomer (R)-ibuprofen
(100 nmol) had no effect on the ﬂexor reﬂexes in either
untreated or CFA-treated rats (Fig. 4).
To determine whether the effect of (S)-ibuprofen was due
to a spinal action or leakage of the drug into the systemic
circulation, (S)-ibuprofen (100 nmol) was injected periph-
erally. Neither intravenous injection nor intraplantar injec-
tion into the inﬂamed hind paw resulted in attenuation of the
ﬂexor reﬂex in CFA-treated animals (data not shown).
3.4. Western blots
The observation that the effect of spinally administered
ibuprofen was limited to animals with peripheral inﬂam-
mation suggested that peripheral inﬂammation induced
Fig. 1. Unilateral injection of CFA into the hind paw of the rat induced
thermal hyperalgesia and increased the number of compound potentials in
the hamstring muscles elicited by a noxious electrical stimulus.
Measurements were made 2–3 days after injection of one hind paw with
CFA. (A) Latency of withdrawal of the hind paw in response to a radiant
thermal stimulus. *Signiﬁcantly shorter than the latency for the ipsilateral
hind paw of untreated rats and the contralateral hind paw of CFA-treated
rats at P , 0:001 (two-way analysis of variance with Tukey’s post hoc test;
n ¼ 17 for untreated group; n ¼ 21 for CFA-treated group). (B) Number of
compoundpotentials in the hamstringmuscles that occurredwithin5 or 120
s following stimulation of the sural nerve at an intensity that activated C-
ﬁbers. *Signiﬁcantly greater than number of potentials evoked in the same
time interval in the untreated group at P , 0:001 (two-way analysis of
variance with Tukey’s post hoc test; n ¼ 20 for untreated group; n ¼ 21 for
CFA-treated group). Values are the mean ^ SEM for each group.
Table 1
Thresholds for activation ofﬁbers in the sural nerve in untreated and CFA-
treated rats
Fiber type Threshold
a
Untreated CFA treated
Ab (mA) 6.1 ^ 0.6 (25) 5.5 ^ 0.4 (28)
Ad (mA) 94.6 ^ 6.3 (25) 92.4 ^ 4.2 (28)
C (mA) 0.46 ^ 0.1 (9) 0.45 ^ 0.1 (10)
aPulse width was 0.1 ms for detection of Ab-ﬁber threshold and 0.5 ms
f o rd e t e c t i o no fA d- and C-ﬁber thresholds. Values represent the
mean ^ SEM; the sample size is shown in parentheses.
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used Western blot analysis to determine whether COX-1
and/or COX-2 protein increased in the spinal cord during
peripheral inﬂammation. Fig. 5 shows examples of COX-1
and COX-2 in samples of dorsal spinal cord. COX-1 protein
was visualized as a major band at approximately 44 kDa and
a minor band at 85 kDa. Quantitative data are reported for
the major band; the data for the minor band were similar.
Single bands of COX-2 (at 50 kDa) and b-tubulin (at 55
kDa) protein were detected in each sample. Densitometric
analysis of bands showed that at 48 h after injection of CFA
the amount of COX-2 in the dorsal half of the spinal cord
increased 60% compared to untreated animals while no
change occurred in the ventral half of the spinal cord
(Table 2). There were no differences in COX-1 protein
between untreated and CFA-treated animals for either the
dorsal or ventral halves of the spinal cord.
4. Discussion
This is the ﬁrst study to show that endogenous cyclo-
oxygenase products generated at the level of the spinal cord
contribute to the maintenance of increased neuronal
excitability that occurs in spinal neurons during peripheral
inﬂammation. Biochemical data showed that the increase in
excitability of spinal neurons occurred in conjunction with
an increase in COX-2 protein in the dorsal spinal cord.
Together these data support the conclusion from behavioral
studies that prostanoids generated by COX-2 at the level of
the spinal cord contribute to the maintenance of hyper-
algesia (Samad et al., 2001).
4.1. Effect of ibuprofen on the nociceptive ﬂexor reﬂex
Evidence that (S)-ibuprofen dose-dependently inhibited
the nociceptive reﬂex and that the R-isomer had no effect
support the conclusion that effects of (S)-ibuprofen were
mediated by inhibition of endogenous cyclo-oxygenase, the
rate-limiting enzyme in the production of prostaglandins.
Prostaglandins have been shown to depolarize the mem-
brane of dorsal horn neurons in vitro (Baba et al., 2001), and
intrathecal administration of (S)-ibuprofen but not the R-
isomer decreases PGE2 release in the spinal cord evoked by
injection of formalin into the paw (Malmberg and Yaksh,
1995). Evidence that a dose of (S)-ibuprofen that inhibited
the nociceptive ﬂexor reﬂex following intrathecal injection
had no effect on the reﬂex following peripheral adminis-
tration support a spinal site of action of the drug when
Fig. 2. Representative recording of the nociceptive ﬂexor reﬂex in an animal with one hind paw injected with CFA 2 days before the recording. Dots below the
recording mark delivery of the electrical stimulus to the sural nerve at an interval of 4 min. The vertical scale represents the number of compound potentials in
the hamstring muscles summed at 1-s intervals. The arrow marks the intrathecal injection of (S)-ibuprofen (100 nmol). Note the decrease in the duration of the
evoked reﬂex following administration of the drug.
Table 2
Change in COX protein in the lumbar spinal cord 48 h after intraplantar
injection of CFA into both hind paws
Spinal sample COX-1 COX-2
Untreated
Dorsal 208 ^ 20 (6) 69 ^ 6 (6)
Ventral 161 ^ 12 (6) 101 ^ 13 (6)
CFA-treated
Dorsal 191 ^ 23 (4) 111 ^ 7 (6)*
Ventral 167 ^ 24 (6) 107 ^ 14 (5)
The L4–L5 segments of the spinal cord were removed from each rat and
divided into dorsal and ventral halves. The amount of COX-1, COX-2 and
b-tubulinin 10 ml samples preparedfromeach half ofeach spinal cordwere
determinedby Western blot analysis. Values for COX protein are expressed
as a percentage of the value for b-tubulin in the same sample and are the
mean ^ SEM for the group; sample size is shown in parentheses.
*P , 0:05, one way analysis of variance with Tukey’s post hoc test to
identify differences between groups.
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the spinal cord was transected at the low thoracic level
indicates that inhibitory effects of (S)-ibuprofen were not
secondary to descending neuronal circuitry that promotes
inhibition. The absence of an effect of (S)-ibuprofen on the
nociceptive ﬂexor reﬂex in untreated rats is consistent with
reports that spinal administration of indomethacin does not
alter responses of dorsal horn neurons to acute noxious
stimuli (Willingale et al., 1997) or behavioral responses to
noxious thermal stimuli (Yamamoto and Nozaki-Taguchi,
1996) in untreated animals. The absence of an effect of
(S)-ibuprofen in untreated rats indicates that basal levels of
prostaglandins do not contribute to synaptic efﬁcacy in
nociceptive transmission from healthy peripheral tissue.
The present studyextends observations of effects of COX
inhibitors on spinal circuitry in models of acute hyperexcit-
ability. Willingale et al. (1997) showed that intrathecal
administration of indomethacin attenuates the C-ﬁber-
induced windup of the nociceptive ﬂexor reﬂex in rats by
40%. Neugebauer et al. (1995) found that ﬂurbiprofen
Fig. 3. Spinal administration of (S)-ibuprofen decreased the activity in the
nociceptive ﬂexor reﬂex in a dose-dependent manner in CFA-treated rats.
Data are the effect of ibuprofen on the short-latency response (A, within 5 s
of nerve stimulation) and long-latency response (B, within 120 s of nerve
stimulation) to electrical stimulation of the sural nerve. Reﬂex responses at
10, 14, 18, 22 and 30 min following injection of the drug were averaged for
each rat to yield a single value for subsequent analysis; n ¼ 5 rats for each
group. Values are the mean ^ SEM for each group. *Signiﬁcantly different
from value for untreated rats at the same dose at P , 0:05 (two-way
analysis of variance with Tukey’s post hoc test).
Fig. 4. Spinal administration of (S)-ibuprofen caused a transient decrease in
the nociceptive ﬂexor reﬂex in CFA-treated rats. The dose (100 nmol) of
(R)- or (S)-ibuprofen was injected intrathecally at time ¼ 0. The reﬂex was
evoked at 4 min intervals. Values are the mean ^ SEM for each group
(n ¼ 5 for vehicle and (S)-ibuprofen; n ¼ 4 for (R)-ibuprofen). *Signiﬁ-
cantly different from vehicle at the same time point,
†signiﬁcantly different
from (R)-ibuprofenat the same time pointat P , 0:05 (two-way analysis of
variance with Tukey’s post hoc test).
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developed following induction of acute inﬂammation of the
knee with carrageenan, and in a comparable model, Mazario
et al. (2001) found that non-selective COX inhibitors
decreased the nociceptive ﬂexor reﬂex. However, in both
studies of acute inﬂammation, changes in neuronal activity
were measured following systemic administration of COX
inhibitors. Therefore the present data provide direct
evidence to support the conclusions of these studies that
effects of COX inhibitors in models of increased spinal cord
excitability are mediated by actions of the drugs at the level
of the spinal cord.
4.2. Differential changes in expression of COX proteins
The occurrence of COX-1 and COX-2 protein in
untreated animals determined in the present study by
Western blot analysis is consistent with several reports of
the constitutive expression of these proteins in the spinal
cord (Willingale et al., 1997; Beiche et al., 1998a;
Ebersberger et al., 1999; Samad et al., 2001; Yaksh et al.,
2001). The apparent lower molecular weight of the
immunoreactive bands visualized in our analysis most
likely represents degradation of the protein during prep-
aration of the samples since protease inhibitors were not
included in the extraction buffer. A band at 43 kD for COX-
2hasbeenreported(Kaufmannetal.,1996;Willingaleetal.,
1997). Identity of the immunoreactive bands as COX
proteins was based on the absence of other immunoreactive
bands on the gels, detection of the homologous, puriﬁed
ovine COX isoform by each antibody, and absorption
controls.
We found an increase in the amount of COX-2 protein in
the spinal cord and no change in COX-1 protein 48 h after
induction of peripheral inﬂammation with CFA. The
selective change in COX-2 is consistent with reports of
increased levels of COX-2 mRNA in the spinal cord within
6 h of injection of CFA into the hind paw (Hay et al., 1997;
Beiche et al., 1998a; Samad et al., 2001) and no change in
COX-1 mRNA (Beiche et al., 1998a). While the change in
expression of mRNA returns to baseline by 3 days after
injection of CFA (Beiche et al., 1998a), the present report
provides evidence that the levels of COX-2 protein remain
increased through 48 hr. The selective increase in COX-2 in
animals with peripheral inﬂammation and the duration of
the elevation suggests that this isoform provides the
biochemical substrate for the inhibition of the nociceptive
ﬂexor reﬂex by ibuprofen 2–3 days after injection of CFA
into the hind paw.
Reports that injection of CFA into the hind paw results in
widespread increases in COX-2 mRNA in the central
nervous system (Beiche et al., 1998a; Samad et al., 2001)
suggested that changes in expression of protein are mediated
by humoral factors, and Samad et al. (2001) provided
evidence that interleukin (IL)-1b is one of these mediators.
However, the present data that the amount of COX-2 protein
increased in the dorsal but not the ventral spinal cord
indicate differential changes by region within the central
nervous system. An increase in expression of COX-2 in the
dorsal spinal cord is consistent with a change in expression
driven by an increase in the activity of nociceptors.
Immunohistochemical analysis shows COX-2 immunoreac-
tivity is dense in the superﬁcial region of the dorsal horn of
the spinal cord (Willingale et al., 1997) where nociceptive
primary afferent neurons terminate, and expression of COX-
2 can be driven by increased excitatory synaptic activity
(Yamagata et al., 1993; Kaufmann et al., 1996). Alterna-
tively, COX-2 protein may not have increased in the ventral
spinal cord if cells in this region do not express receptors for
IL-1b.
4.3. Role of prostaglandins in nociceptive processing
The present report provides support for a role of
prostaglandins, generated at the level of the spinal cord, in
central mechanisms of hyperalgesia. A model proposed by
Yaksh et al. (1999) is that activation of nociceptors drives
the release of substance P from primary afferent neurons,
and substance P activates receptors on cells within the spinal
cord to generate the production of prostaglandins. Evidence
in support of this model is that intrathecal administration of
substance P evokes the release of prostaglandins in the
spinal cord (Malmberg and Yaksh, 1992b; Yaksh et al.,
Fig. 5. Representative images of Western blots of COX-1 and COX-2
protein from dorsal halves of the rat lumbar spinal cord. Ten ml of spinal
cord extract were submitted to SDS-PAGE and Western blot analysis. A
major and a minor band were visualized with the COX-1 antibody; only one
band was visualized with the COX-2 antibody. The sample identiﬁed as
CFA was collected 48 h after injection of CFA into both hind paws.
V.S. Seybold et al. / Pain 105 (2003) 47–55 532001) and intrathecal ibuprofen blocks substance P-induced
hyperalgesia (Yaksh et al., 2001). COX-2 is responsible for
generating the prostaglandins that mediate the effect of
substance P in the spinal cord (Yaksh et al., 2001).
Furthermore, prostaglandins in the spinal cord have a
feed-forward effect on this pathway by enhancing release of
substance P from primary afferent neurons (Vasko et al.,
1993). Data obtained using the nociceptive ﬂexor reﬂex
support this model: Intrathecal administration of antagonists
of neurokinin-1 and 2 receptors have no effect on the
nociceptive ﬂexor reﬂex in untreated animals but attenuate
the reﬂex in animals with peripheral inﬂammation (Parsons
et al., 1996; Jia and Seybold, 1997). Parallel results occurred
following intrathecal administration of a COX inhibitor
(present report). Thus, in untreated animals, the amount of
substance P released in response to an acute nociceptive
stimulus, or the level of cyclo-oxygenase in the spinal cord
innervated by afferents from non-inﬂamed tissue, are not
sufﬁcient to affect synaptic efﬁcacy. However, increased
release of substance P and increased levels of prostaglandins
generated by increased COX-2 protein in spinal cord are
capable of augmenting synaptic transmission of primary
afferents from inﬂamed tissue thereby contributing to
hyperalgesia.
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